The changing landscape for patients with relapsed/refractory acute myeloid leukaemia

Purpose of review The treatment of patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) has been an unequal challenge for many decades. Although significant progress has been made in the discovery of the mechanisms underlying the molecular pathogenesis of the disease, more than 50% of AML patients still die, mostly from relapsed disease. Currently, the only potential curative option for patients with R/R AML remains allogeneic bone marrow transplantation in second complete remission, which is far being easy to achieve, mainly for patients with primary induction failure or older than 65 years. The purpose of this review is to discuss recent advances in the management of patients with R/R AML, with particular emphasis to new therapeutic options that are replacing conventional salvage chemotherapy. Recent findings The development of new agents selectively targeting molecular abnormalities offer more effective and less toxic alternative to chemotherapy, potentially useful as a bridge to allogeneic stem cell transplantation in second complete remission. The recent approval of new drugs for R/R is transforming the paradigm of care we have relied on for the past 50 years. Ongoing clinical trials will tell us how bright is the future for R/R AML patients.

Automated summary

Treating patients with relapsed or refractory acute myeloid leukaemia has been a challenging task for many years, with the only potential curative option being allogeneic bone marrow transplantation. Recent advances in targeting molecular abnormalities with new agents offer a less toxic alternative to conventional chemotherapy, potentially serving as a bridge to transplantation. Ongoing clinical trials will shed light on the future prospects for these patients.